查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1600539

生物模拟市场：按产品、产品模型、最终用户、应用划分 - 2025-2030 年全球预测

Biosimulation Market by Offering (Services, Software), Delivery Model (Ownership Models, Subscription Models), End-User, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年生物模拟市场价值为38.1亿美元，预计到2024年将达到44亿美元，复合年增长率为14.55%，预计到2030年将达到98.7亿美元。

生物模拟涉及使用电脑辅助预测模型来模拟生物过程，并且正在成为一种可以简化药物开发和个人化医疗的变革工具。其范围包括预测人体对药物反应的药物动力学和动态模型，使其在製药、医疗和学术应用中具有无价的价值。对生物模拟的需求源自于能够减少与传统临床测试相关的成本和时间，同时提高生物预测的准确性。它可应用于药物发现、心臟安全评估和疾病建模，最终用途扩展到生物技术公司、研究机构和监管机构。市场开拓的驱动力是药物开发中越来越多地采用生物模拟、慢性病的流行以及计算技术的进步。目前的机会来自与人工智慧的集成，以提高预测准确性、增加对个人化医疗的投资，以及将生物模拟应用扩展到肿瘤学和神经病学等新的治疗领域。然而，挑战包括实施成本高、潜在最终用户意识低以及对资料隐私的担忧，这些都会抑製成长。创新机会在于增强机器学习演算法、开发更全面的多尺度模型以及改进资料整合技术以提高预测能力。为了实现业务成长，公司应专注于与研究机构建立伙伴关係关係以促进技术进步，并投资教育相关人员了解生物模拟的好处。该市场的性质是动态的、研究集中的，其特点是技术快速进步，并受到对药物开发效率的持续需求的驱动。应对挑战并利用生物模拟的机会对于相关人员在不断发展的医疗保健领域保持竞争力至关重要。

主要市场统计
基准年[2023] 38.1亿美元
预测年份 [2024] 44亿美元
预测年份 [2030] 98.7亿美元
复合年增长率（%） 14.55%

市场动态：揭示快速发展的生物模拟市场的关键市场洞察

供需的动态交互作用正在改变生物模拟市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 越来越重视个人化医疗的研究
    • 支持监管部门核准使用生物模拟来加强安全药物开发
  • 市场限制因素
    • 由于生物模拟的引入和技术发展导致价格上涨
  • 市场机会
    • 模拟解决方案不断进步，以增强新的生物治疗方法
    • 加大药物研发及药物检测投入
  • 市场问题
    • 缺乏意识且复杂性无法产生准确的结果

波特五力：驾驭生物模拟市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解生物模拟市场的外部影响

外部宏观环境因素在塑造生物模拟市场的绩效动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析：了解生物模拟市场的竞争格局

对生物模拟市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵：生物模拟市场供应商绩效评估

FPNV定位矩阵是评估生物模拟市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：绘製生物模拟市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对生物模拟市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1.市场渗透率：对当前市场环境的详细审查，主要企业的广泛资料，评估他们在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 专注于个人化医疗研究
      • 监管部门核准使用生物模拟加速安全药物开发
    • 抑制因素
      • 与生物模拟安装和技术开发相关的价格上涨
    • 机会
      • 模拟解决方案不断进步，以增强新的生物疗法
      • 加大药物研发及药物检测投入
    • 任务
      • 复杂性和缺乏产生准确结果的意识
  • 市场区隔分析
    • 产品：生物模拟中软体使用的增加为模型建构、模拟、分析和视觉化提供了平台
    • 交付模型：生物模拟中越来越倾向于所有权模型来为使用者提供完全的控制。
    • 最终用户：扩大生物模拟在製药和生物技术公司的采用
    • 应用：扩大生物模拟在药物开发的应用
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章生物模拟市场：依产品分类

  • 介绍
  • 服务
    • 合约服务
    • 内部服务
  • 软体
    • 分子建模与模拟软体
    • PBPK建模模拟软体
    • PK/PD建模与模拟软体
    • 毒性预测软体
    • 检验设计软体

第七章生物模拟市场：依提供的模型分类

  • 介绍
  • 所有权模式
  • 订阅模式

第 8 章生物模拟市场：依最终用户分类

  • 介绍
  • 合约研究组织
  • 製药和生物技术公司
  • 监管机构
  • 研究所

第九章生物模拟市场：依应用分类

  • 介绍
  • 药物开发
    • 临床检查
    • 临床前测试
      • ADME/毒性
      • PK/PD
  • 药物发现
    • 候选人识别和优化
    • 目标识别与检验

第10章美洲生物模拟市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太生物模拟市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲生物模拟市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Certara 收购 Chemaxon 以加强药物发现和生物模拟能力
    • Simulations Plus 以 1 亿美元收购 Pro-Pro-ficiency Holdings, Inc.，扩大药物开发能力。
    • Cellworks 在田纳西州推出新的 CLIA 认证实验室，透过生物模拟技术和专家领导力增强个人化 NSCLC 治疗
    • Certara 发布 Pirana Modeling Workbench 23.10.1，具有先进的机器学习和新的 VPC GUI
    • Certara 和 DNDi 联手加快资料提交速度并加快延迟治疗患者的药物核准
    • Certara 发布用于药物开发的 Phoenix模拟软体8.4 版
    • Certara 透过 AI 药物发现增强 CODEX 平台功能
    • Simulations Plus 推出新的综合肺部疾病软体和服务包，旨在简化药物开发并改善患者治疗结果
    • Simulations Plus 取得美国FDA 续签 DILIsym 软体许可证
    • Simulations Plus 建立伙伴关係，透过应用 AI/ML 技术设计新化合物
    • Simulations Plus 发表重新设计的 NAFLDsym QSP 软体工具
    • Cellworks 进军精准医疗领域，加速癌症治疗的发展并重振被搁置的药物资产
    • Certara 收购 Vyasa，一家提供预测以加速科学创新的人工智慧公司
    • Applied BioMath LLC 宣布与 SpringWorks Therapeutics 合作进行多发性骨髓瘤的系统药理学建模
    • Applied BioMath LLC 宣布继续与摄氏度疗法在发炎性肠道疾病的系统药理学建模方面合作
    • GNS 和施维雅宣布人工智慧合作，推动多发性骨髓瘤的药物发现和临床开发
    • Cadence 透过收购计算分子设计领域的先驱领导者 OpenEye Scientific 进军分子模拟领域
    • Resolution Medical 收购 LifeTec 集团
    • Colorcon Ventures 投资人工智慧驱动的生物模拟公司 VeriSIM Life
  • 战略分析和建议
    • 赛默飞世尔科技有限公司

公司名单

  • Advanced Chemistry Development, Inc.
  • Aitia
  • Allucent
  • Biomed Simulation, Inc.
  • BioSimulation Consulting Inc.
  • Cadence Design Systems, Inc.
  • Cell Works Group, Inc.
  • Certara, Inc.
  • Chemical Computing Group ULC
  • Compugen Ltd.
  • Crystal Pharmatech Co., Ltd.
  • Dassault Systemes SE
  • Genedata AG
  • INOSIM Software GmbH by ZETA Holding
  • Instem PLC
  • Laboratory Corporation of America Holdings
  • Model Vitals
  • Physiomics PLC
  • Quotient Sciences Limited
  • Resolution Medical
  • Rosa & Co LLC
  • Schrodinger, Inc.
  • Simulations Plus, Inc.
  • Thermo Fisher Scientific Inc.
  • VeriSIM Life.
  • VIRTUALMAN
  • Yokogawa Electric Corporation
Product Code: MRR-2D64BA93AB17

The Biosimulation Market was valued at USD 3.81 billion in 2023, expected to reach USD 4.40 billion in 2024, and is projected to grow at a CAGR of 14.55%, to USD 9.87 billion by 2030.

Biosimulation involves the use of computer-aided predictive models to simulate biological processes, appearing as a transformative tool capable of streamlining drug development and personalized medicine. The scope involves pharmacokinetic and pharmacodynamic models that predict the body's reaction to drugs, making it invaluable in pharmaceuticals, healthcare, and academia. The necessity of biosimulation arises from its ability to reduce the costs and time associated with traditional clinical trials while enhancing accuracy in biological predictions. It finds application in drug discovery, cardiac safety assessment, and disease modeling, with end-use spread across biotechnology companies, research organizations, and regulatory institutes. Market growth is driven by the increasing adoption of biosimulation in drug development, growing chronic disease prevalence, and advances in computational technology. Current opportunities arise from integration with AI to enhance predictive accuracy, growing investments in personalized medicine, and expanding biosimulation applications into new therapeutic areas like oncology and neurology. However, challenge factors include high implementation costs, limited awareness among potential end-users, and data privacy concerns, which could impede growth. Innovation opportunities lie in enhancing machine learning algorithms, developing more comprehensive and multi-scale models, and improving data integration techniques to enhance predictive capabilities. For business growth, companies should focus on forming partnerships with research institutions for technology advancements and invest in educating stakeholders about the benefits of biosimulation. The nature of this market is dynamic and research-intensive, characterized by rapid technological advances and driven by the constant need for efficiency in drug development. Addressing the challenges and capitalizing on opportunities in biosimulation will be vital for stakeholders to maintain a competitive edge in the evolving healthcare landscape.

KEY MARKET STATISTICS
Base Year [2023] USD 3.81 billion
Estimated Year [2024] USD 4.40 billion
Forecast Year [2030] USD 9.87 billion
CAGR (%) 14.55%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Biosimulation Market

The Biosimulation Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing emphasis on research of personalized medicine
    • Supportive regulatory approvals for use of biosimulation to enhance the development of safe medicines
  • Market Restraints
    • Upscaled prices involved in installations and technique developments for biosimulation
  • Market Opportunities
    • Ongoing advancements in simulation solutions to enhance the novel biologic therapies
    • Rising investments for drug developments and drug testings
  • Market Challenges
    • Lack of awareness coupled with complexities for creating accurate outcomes

Porter's Five Forces: A Strategic Tool for Navigating the Biosimulation Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Biosimulation Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Biosimulation Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Biosimulation Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Biosimulation Market

A detailed market share analysis in the Biosimulation Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Biosimulation Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Biosimulation Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Biosimulation Market

A strategic analysis of the Biosimulation Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Biosimulation Market, highlighting leading vendors and their innovative profiles. These include Advanced Chemistry Development, Inc., Aitia, Allucent, Biomed Simulation, Inc., BioSimulation Consulting Inc., Cadence Design Systems, Inc., Cell Works Group, Inc., Certara, Inc., Chemical Computing Group ULC, Compugen Ltd., Crystal Pharmatech Co., Ltd., Dassault Systemes SE, Genedata AG, INOSIM Software GmbH by ZETA Holding, Instem PLC, Laboratory Corporation of America Holdings, Model Vitals, Physiomics PLC, Quotient Sciences Limited, Resolution Medical, Rosa & Co LLC, Schrodinger, Inc., Simulations Plus, Inc., Thermo Fisher Scientific Inc., VeriSIM Life., VIRTUALMAN, and Yokogawa Electric Corporation.

Market Segmentation & Coverage

This research report categorizes the Biosimulation Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Offering, market is studied across Services and Software. The Services is further studied across Contract Services and In-House Services. The Software is further studied across Molecular Modeling & Simulation Software, PBPK Modeling & Simulation Software, PK/PD Modeling & Simulation Software, Toxicity Prediction Software, and Trial Design Software.
  • Based on Delivery Model, market is studied across Ownership Models and Subscription Models.
  • Based on End-User, market is studied across Contract Research Organizations, Pharmaceutical & Biotechnology Companies, Regulatory Authorities, and Research Institutes.
  • Based on Application, market is studied across Drug Development and Drug Discovery. The Drug Development is further studied across Clinical Trials and Preclinical Testing. The Preclinical Testing is further studied across ADME/Tox and PK/PD. The Drug Discovery is further studied across Lead Identification & Optimization and Target Identification & Validation.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing emphasis on research of personalized medicine
      • 5.1.1.2. Supportive regulatory approvals for use of biosimulation to enhance the development of safe medicines
    • 5.1.2. Restraints
      • 5.1.2.1. Upscaled prices involved in installations and technique developments for biosimulation
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing advancements in simulation solutions to enhance the novel biologic therapies
      • 5.1.3.2. Rising investments for drug developments and drug testings
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of awareness coupled with complexities for creating accurate outcomes
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Offering: Rising usage of software in biosimulation to provide a platform for model building, simulation, analysis, and visualization
    • 5.2.2. Delivery Model: Growing preference for ownership model in biosimulation for providing full control to users
    • 5.2.3. End-User: Expanding adoption of biosimulation among pharmaceutical & biotechnology companies
    • 5.2.4. Application: Increasing application of biosimulation for drug development
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Biosimulation Market, by Offering

  • 6.1. Introduction
  • 6.2. Services
    • 6.2.1. Contract Services
    • 6.2.2. In-House Services
  • 6.3. Software
    • 6.3.1. Molecular Modeling & Simulation Software
    • 6.3.2. PBPK Modeling & Simulation Software
    • 6.3.3. PK/PD Modeling & Simulation Software
    • 6.3.4. Toxicity Prediction Software
    • 6.3.5. Trial Design Software

7. Biosimulation Market, by Delivery Model

  • 7.1. Introduction
  • 7.2. Ownership Models
  • 7.3. Subscription Models

8. Biosimulation Market, by End-User

  • 8.1. Introduction
  • 8.2. Contract Research Organizations
  • 8.3. Pharmaceutical & Biotechnology Companies
  • 8.4. Regulatory Authorities
  • 8.5. Research Institutes

9. Biosimulation Market, by Application

  • 9.1. Introduction
  • 9.2. Drug Development
    • 9.2.1. Clinical Trials
    • 9.2.2. Preclinical Testing
      • 9.2.2.1. ADME/Tox
      • 9.2.2.2. PK/PD
  • 9.3. Drug Discovery
    • 9.3.1. Lead Identification & Optimization
    • 9.3.2. Target Identification & Validation

10. Americas Biosimulation Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Biosimulation Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Biosimulation Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Certara to acquire Chemaxon to enhance drug discovery and biosimulation capabilities
    • 13.3.2. Simulations Plus expands drug development capabilities with USD 100 million acquisition of Pro-Pro-ficiency Holdings, Inc.
    • 13.3.3. Cellworks unveils new CLIA-certified lab in Tennessee enhancing personalized NSCLC treatment with biosimulation technology and expert leadership
    • 13.3.4. Certara launches Pirana Modeling Workbench 23.10.1 with advanced machine learning and new VPC GUI
    • 13.3.5. Certara and DNDi Partnering to Fast-track Data Submissions and Accelerate Drug Approvals for Neglected Patients
    • 13.3.6. Certara Launches Version 8.4 of Phoenix Biosimulation Software for Drug Development
    • 13.3.7. Certara Amplifies CODEX Platform Capabilities with AI for Drug Discovery
    • 13.3.8. Simulations Plus Launches New Integrated Pulmonary Software and Services Package to Streamline Drug Development and Improve Patient Outcomes
    • 13.3.9. Simulations Plus Receives U.S. FDA Renewal for DILIsym Software Licenses
    • 13.3.10. Simulations Plus Enters Partnership to Apply AI/ML Technologies to Design Novel Compounds
    • 13.3.11. Simulations Plus Releases Redesigned NAFLDsym QSP Software Tool
    • 13.3.12. Cellworks Expands into Precision Pharma to Accelerate the Development of Cancer Drugs and Revive Shelved Pharmaceutical Assets
    • 13.3.13. Certara Acquires Vyasa, an Artificial Intelligence Company that Delivers Predictions to Accelerate Scientific Innovation
    • 13.3.14. Applied BioMath, LLC Announces Collaboration with SpringWorks Therapeutics, Inc. for Systems Pharmacology Modeling in Multiple Myeloma
    • 13.3.15. Applied BioMath, LLC Announces a Continuation of their Collaboration with Celsius Therapeutics for Systems Pharmacology Modeling in Inflammatory Bowel Disease
    • 13.3.16. GNS and Servier Announce AI Collaboration to Advance Multiple Myeloma Drug Discovery and Clinical Development
    • 13.3.17. Cadence Expands into Molecular Simulation with Acquisition of OpenEye Scientific, a Pioneering Leader in Computational Molecular Design
    • 13.3.18. Resolution Medical Acquires LifeTec Group
    • 13.3.19. Colorcon Ventures Invests in AI-Driven Bio-simulation Company VeriSIM Life
  • 13.4. Strategy Analysis & Recommendation
    • 13.4.1. Thermo Fisher Scientific Inc.

Companies Mentioned

  • 1. Advanced Chemistry Development, Inc.
  • 2. Aitia
  • 3. Allucent
  • 4. Biomed Simulation, Inc.
  • 5. BioSimulation Consulting Inc.
  • 6. Cadence Design Systems, Inc.
  • 7. Cell Works Group, Inc.
  • 8. Certara, Inc.
  • 9. Chemical Computing Group ULC
  • 10. Compugen Ltd.
  • 11. Crystal Pharmatech Co., Ltd.
  • 12. Dassault Systemes SE
  • 13. Genedata AG
  • 14. INOSIM Software GmbH by ZETA Holding
  • 15. Instem PLC
  • 16. Laboratory Corporation of America Holdings
  • 17. Model Vitals
  • 18. Physiomics PLC
  • 19. Quotient Sciences Limited
  • 20. Resolution Medical
  • 21. Rosa & Co LLC
  • 22. Schrodinger, Inc.
  • 23. Simulations Plus, Inc.
  • 24. Thermo Fisher Scientific Inc.
  • 25. VeriSIM Life.
  • 26. VIRTUALMAN
  • 27. Yokogawa Electric Corporation

LIST OF FIGURES

  • FIGURE 1. BIOSIMULATION MARKET RESEARCH PROCESS
  • FIGURE 2. BIOSIMULATION MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BIOSIMULATION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIOSIMULATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BIOSIMULATION MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BIOSIMULATION MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BIOSIMULATION MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BIOSIMULATION MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES BIOSIMULATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES BIOSIMULATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. BIOSIMULATION MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. BIOSIMULATION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BIOSIMULATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BIOSIMULATION MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BIOSIMULATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIOSIMULATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BIOSIMULATION MARKET DYNAMICS
  • TABLE 7. GLOBAL BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BIOSIMULATION MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIOSIMULATION MARKET SIZE, BY CONTRACT SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BIOSIMULATION MARKET SIZE, BY IN-HOUSE SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BIOSIMULATION MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIOSIMULATION MARKET SIZE, BY MOLECULAR MODELING & SIMULATION SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BIOSIMULATION MARKET SIZE, BY PBPK MODELING & SIMULATION SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIOSIMULATION MARKET SIZE, BY PK/PD MODELING & SIMULATION SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BIOSIMULATION MARKET SIZE, BY TOXICITY PREDICTION SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIOSIMULATION MARKET SIZE, BY TRIAL DESIGN SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BIOSIMULATION MARKET SIZE, BY OWNERSHIP MODELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIOSIMULATION MARKET SIZE, BY SUBSCRIPTION MODELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIOSIMULATION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BIOSIMULATION MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BIOSIMULATION MARKET SIZE, BY REGULATORY AUTHORITIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BIOSIMULATION MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL BIOSIMULATION MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL BIOSIMULATION MARKET SIZE, BY ADME/TOX, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL BIOSIMULATION MARKET SIZE, BY PK/PD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL BIOSIMULATION MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL BIOSIMULATION MARKET SIZE, BY TARGET IDENTIFICATION & VALIDATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS BIOSIMULATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 84. MEXICO BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. UNITED STATES BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES BIOSIMULATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 108. AUSTRALIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. AUSTRALIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 112. AUSTRALIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 115. CHINA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 116. CHINA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 117. CHINA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 118. CHINA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. CHINA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. CHINA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 121. CHINA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 122. CHINA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 123. INDIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 124. INDIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 125. INDIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 126. INDIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 127. INDIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. INDIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. INDIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 130. INDIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 131. INDIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 132. INDONESIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 133. INDONESIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 134. INDONESIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 135. INDONESIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 136. INDONESIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. INDONESIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. INDONESIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 139. INDONESIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 140. INDONESIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 141. JAPAN BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 142. JAPAN BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 143. JAPAN BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 144. JAPAN BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 145. JAPAN BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. JAPAN BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. JAPAN BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 148. JAPAN BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 149. JAPAN BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 150. MALAYSIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 151. MALAYSIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 152. MALAYSIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 153. MALAYSIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 154. MALAYSIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 155. MALAYSIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. MALAYSIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 157. MALAYSIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 158. MALAYSIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 159. PHILIPPINES BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 160. PHILIPPINES BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 161. PHILIPPINES BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 162. PHILIPPINES BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 163. PHILIPPINES BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. PHILIPPINES BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. PHILIPPINES BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 166. PHILIPPINES BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 167. PHILIPPINES BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 168. SINGAPORE BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 169. SINGAPORE BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 170. SINGAPORE BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 171. SINGAPORE BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 172. SINGAPORE BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 173. SINGAPORE BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 174. SINGAPORE BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 175. SINGAPORE BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 176. SINGAPORE BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 177. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 178. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 179. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 180. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 181. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 184. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 185. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 186. TAIWAN BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 187. TAIWAN BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 188. TAIWAN BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 189. TAIWAN BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 190. TAIWAN BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 191. TAIWAN BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 192. TAIWAN BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 193. TAIWAN BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 194. TAIWAN BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 195. THAILAND BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 196. THAILAND BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 197. THAILAND BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 198. THAILAND BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 199. THAILAND BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 200. THAILAND BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 201. THAILAND BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 202. THAILAND BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 203. THAILAND BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 204. VIETNAM BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 205. VIETNAM BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 206. VIETNAM BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 207. VIETNAM BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 208. VIETNAM BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 209. VIETNAM BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 210. VIETNAM BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 211. VIETNAM BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 212. VIETNAM BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 223. DENMARK BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 224. DENMARK BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 225. DENMARK BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 226. DENMARK BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 227. DENMARK BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 228. DENMARK BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 229. DENMARK BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 230. DENMARK BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 231. DENMARK BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 232. EGYPT BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 233. EGYPT BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 234. EGYPT BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 235. EGYPT BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 236. EGYPT BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 237. EGYPT BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 238. EGYPT BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 239. EGYPT BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 240. EGYPT BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 241. FINLAND BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 242. FINLAND BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 243. FINLAND BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 244. FINLAND BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 245. FINLAND BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 246. FINLAND BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 247. FINLAND BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 248. FINLAND BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 249. FINLAND BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 250. FRANCE BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 251. FRANCE BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 252. FRANCE BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 253. FRANCE BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 254. FRANCE BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 255. FRANCE BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 256. FRANCE BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 257. FRANCE BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 258. FRANCE BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 259. GERMANY BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 260. GERMANY BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 261. GERMANY BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 262. GERMANY BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 263. GERMANY BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 264. GERMANY BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 265. GERMANY BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 266. GERMANY BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 267. GERMANY BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 268. ISRAEL BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 269. ISRAEL BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 270. ISRAEL BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 271. ISRAEL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 272. ISRAEL BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 273. ISRAEL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 274. ISRAEL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 275. ISRAEL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 276. ISRAEL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 277. ITALY BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 278. ITALY BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 279. ITALY BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 280. ITALY BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 281. ITALY BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 282. ITALY BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 283. ITALY BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 284. ITALY BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 285. ITALY BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 286. NETHERLANDS BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 287. NETHERLANDS BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 288. NETHERLANDS BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 289. NETHERLANDS BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 290. NETHERLANDS BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 291. NETHERLANDS BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 292. NETHERLANDS BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 293. NETHERLANDS BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 294. NETHERLANDS BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 295. NIGERIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 296. NIGERIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 297. NIGERIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 298. NIGERIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 299. NIGERIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 300. NIGERIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 301. NIGERIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 302. NIGERIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 303. NIGERIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 304. NORWAY BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 305. NORWAY BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 306. NORWAY BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 307. NORWAY BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 308. NORWAY BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 309. NORWAY BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 310. NORWAY BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 311. NORWAY BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 312. NORWAY BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 313. POLAND BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 314. POLAND BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 315. POLAND BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 316. POLAND BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 317. POLAND BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 318. POLAND BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 319. POLAND BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 320. POLAND BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 321. POLAND BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 322. QATAR BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 323. QATAR BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 324. QATAR BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 325. QATAR BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 326. QATAR BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 327. QATAR BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 328. QATAR BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 329. QATAR BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 330. QATAR BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 331. RUSSIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 332. RUSSIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 333. RUSSIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 334. RUSSIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 335. RUSSIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 336. RUSSIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 337. RUSSIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 338. RUSSIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 339. RUSSIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 340. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 341. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 342. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 343. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 344. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 345. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 346. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 347. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 348. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 349. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 350. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 351. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 352. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 353. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 354. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 355. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 356. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 357. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 358. SPAIN BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 359. SPAIN BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 360. SPAIN BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 361. SPAIN BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 362. SPAIN BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 363. SPAIN BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 364. SPAIN BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 365. SPAIN BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 366. SPAIN BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 367. SWEDEN BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 368. SWEDEN BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 369. SWEDEN BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 370. SWEDEN BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 371. SWEDEN BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD